NCT05681598View on ClinicalTrials.gov

Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa

NACompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

May 16, 2020

Study Completion Date

May 16, 2020

Conditions
Sickle-Cell Anaemia
Interventions
DRUG

Hydroxyurea

The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.

Trial Locations (1)

Unknown

University of Kinshasa, Kinshasa

All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

University of Kinshasa

OTHER

NCT05681598 - Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa | Biotech Hunter | Biotech Hunter